Skip to main content

Calidi Biotherapeutics, Inc. (“Calidi”) is a clinical-stage immuno-oncology company revolutionizing the development and commercialization of novel allogenic stem cell-based platforms for delivery and potentiation of oncolytic viruses in the treatment of cancer. Calidi directly addresses a critical obstacle in oncolytic virotherapy: the oncolytic virus inactivation by the patient’s immune system. We are developing a pipeline of “off-the-shelf” product candidates using our platform of allogeneic stem cell technologies and oncolytic viruses (vaccinia virus and adenovirus). These products are designed to: 

  • Protect oncolytic viruses from complement inactivation and innate immune cell inactivation by the patient’s immune system
  • Support oncolytic viral amplification in the allogeneic stem cells
  • Modify the tumor microenvironment to allow effective cell targeting and viral amplification at the tumor sites for an extended period